Previous 10 | Next 10 |
Investing in IPO stocks can be fun, but also risky. There can be a scarcity of information about a brand new equity. And sometimes the underwriters intentionally lowball the value of a company, in order to hype the stock (and reward the bank's clients who bought shares on the cheap). None...
Written by Daniel Cohen and Scott Matusow Karuna Therapeutics (KRTX), NextCure (NXTC), and Constellation Pharmaceuticals (CNST) are but the latest examples of how the biotech sector has been heating up. All 3 of these names have seen very strong stock appreciation on earl...
BELTSVILLE, Md., Nov. 26, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company ...
Biotech investors know not to place too much value on early-stage results from a small number of patients, but that doesn't stop Mr. Market from getting carried away from time to time. NextCure (NASDAQ: NXTC) became the latest example of why that's rarely a great idea. Preliminary res...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
BELTSVILLE, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of it...
NextCure (NASDAQ: NXTC ) prices its public offering of ~4.1M common shares at $36.75 per share, expected to yield gross proceeds of ~$150M. Underwriters' over-allotment is an additional ~612K shares. Closing date is November 19. More news on: NextCure, Inc., Healthcare stocks news, Stock...
BELTSVILLE, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its pu...
NextCure is down after trial data NextCure ( NXTC ) is a recently IPO-ed small cap that has come under my radar mainly because of its tremendous rise after the IPO lock-up period. That is a very good sign; it basically shows the confidence insiders must have on the stock, since they did not ...
Gainers: CDLX +20.8% . TWOU +14.6% . DDOG +14.2% . VRAY +9.3% . NBRV +8.4% . More news on: Cardlytics, Inc., 2U, Inc., Datadog, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...